Efficacy of amlodipine in pediatric bone marrow transplant patients

Sohail Khattak; John W. Rogan; E. Fred Saunders; Jochen G.W. Theis; Gerald S. Arbus; Gideon Koren

doi:10.1177/000992289803700105

Efficacy of amlodipine in pediatric bone marrow transplant patients

Sohail Khattak, John W. Rogan, E. Fred Saunders, Jochen G.W. Theis, Gerald S. Arbus, Gideon Koren

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Abstract

The calcium antagonist amlodipine may have the potential for expanded use in children owing to its physiochemistry and pharmacokinetic profile that facilitates once-daily dosing in a liquid formulation. Its safety and efficacy have not been previously evaluated in children. A retrospective analysis of 15 pediatric bone marrow transplant patients who had amlodipine incorporated into their antihypertensive drug regimen reveals significantly lower blood pressure as compared with baseline therapy (123.5 ± 2.1 mmHg and 117.2 ± 2.2 mmHg, systolic blood pressure before and during amlodipine, P<0.05; 81.5 ± 1.8 mmHg and 75.5 ± 2.6 mmHg, diastolic blood pressure before and during amlodipine, P<0.05). Amlodipine provided improved blood pressure control in this cohort and may provide a valuable pharmacologic alternative for treatment of pediatric hypertension.

Original language	English
Pages (from-to)	31-36
Number of pages	6
Journal	Clinical Pediatrics
Volume	37
Issue number	1
DOIs	https://doi.org/10.1177/000992289803700105
State	Published - 1998
Externally published	Yes

Access to Document

10.1177/000992289803700105

Cite this

@article{cffc01cb6e0f4fdb90c095cacfabc622,

title = "Efficacy of amlodipine in pediatric bone marrow transplant patients",

abstract = "The calcium antagonist amlodipine may have the potential for expanded use in children owing to its physiochemistry and pharmacokinetic profile that facilitates once-daily dosing in a liquid formulation. Its safety and efficacy have not been previously evaluated in children. A retrospective analysis of 15 pediatric bone marrow transplant patients who had amlodipine incorporated into their antihypertensive drug regimen reveals significantly lower blood pressure as compared with baseline therapy (123.5 ± 2.1 mmHg and 117.2 ± 2.2 mmHg, systolic blood pressure before and during amlodipine, P<0.05; 81.5 ± 1.8 mmHg and 75.5 ± 2.6 mmHg, diastolic blood pressure before and during amlodipine, P<0.05). Amlodipine provided improved blood pressure control in this cohort and may provide a valuable pharmacologic alternative for treatment of pediatric hypertension.",

author = "Sohail Khattak and Rogan, {John W.} and {Fred Saunders}, E. and Theis, {Jochen G.W.} and Arbus, {Gerald S.} and Gideon Koren",

year = "1998",

doi = "10.1177/000992289803700105",

language = "אנגלית",

volume = "37",

pages = "31--36",

journal = "Clinical Pediatrics",

issn = "0009-9228",

publisher = "SAGE Publications Inc.",

number = "1",

}

TY - JOUR

T1 - Efficacy of amlodipine in pediatric bone marrow transplant patients

AU - Khattak, Sohail

AU - Rogan, John W.

AU - Fred Saunders, E.

AU - Theis, Jochen G.W.

AU - Arbus, Gerald S.

AU - Koren, Gideon

PY - 1998

Y1 - 1998

N2 - The calcium antagonist amlodipine may have the potential for expanded use in children owing to its physiochemistry and pharmacokinetic profile that facilitates once-daily dosing in a liquid formulation. Its safety and efficacy have not been previously evaluated in children. A retrospective analysis of 15 pediatric bone marrow transplant patients who had amlodipine incorporated into their antihypertensive drug regimen reveals significantly lower blood pressure as compared with baseline therapy (123.5 ± 2.1 mmHg and 117.2 ± 2.2 mmHg, systolic blood pressure before and during amlodipine, P<0.05; 81.5 ± 1.8 mmHg and 75.5 ± 2.6 mmHg, diastolic blood pressure before and during amlodipine, P<0.05). Amlodipine provided improved blood pressure control in this cohort and may provide a valuable pharmacologic alternative for treatment of pediatric hypertension.

AB - The calcium antagonist amlodipine may have the potential for expanded use in children owing to its physiochemistry and pharmacokinetic profile that facilitates once-daily dosing in a liquid formulation. Its safety and efficacy have not been previously evaluated in children. A retrospective analysis of 15 pediatric bone marrow transplant patients who had amlodipine incorporated into their antihypertensive drug regimen reveals significantly lower blood pressure as compared with baseline therapy (123.5 ± 2.1 mmHg and 117.2 ± 2.2 mmHg, systolic blood pressure before and during amlodipine, P<0.05; 81.5 ± 1.8 mmHg and 75.5 ± 2.6 mmHg, diastolic blood pressure before and during amlodipine, P<0.05). Amlodipine provided improved blood pressure control in this cohort and may provide a valuable pharmacologic alternative for treatment of pediatric hypertension.

UR - http://www.scopus.com/inward/record.url?scp=0031883372&partnerID=8YFLogxK

U2 - 10.1177/000992289803700105

DO - 10.1177/000992289803700105

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 9475697

AN - SCOPUS:0031883372

SN - 0009-9228

VL - 37

SP - 31

EP - 36

JO - Clinical Pediatrics

JF - Clinical Pediatrics

IS - 1

ER -

Efficacy of amlodipine in pediatric bone marrow transplant patients

Abstract

Access to Document

Other files and links

Fingerprint

Cite this